Amneal Pharmaceuticals, Inc. (AMRX) raised its 2026 revenue outlook by $50 million, now projecting between $3.1 billion and $3.2 billion, during its Q2 2026 earnings call presentation.
The company's management characterized the current period as the most transformative in its history, citing a deliberate shift from legacy oral solids toward complex, high-value medicines.
The updated guidance assumes high single-digit growth in both the Specialty and Affordable Medicines segments.
Amneal's revised 2026 revenue outlook.
Operational updates and manufacturing expansion
Amneal's Brookhaven, US, site was selected for the US Food and Drug Administration's (FDA) PreCheck Pilot Program, a move the company stated validates its US manufacturing quality and readiness for upcoming sterile injectable expansion.
In the Affordable Medicines segment, demand for transdermal patches increased following revised US FDA guidance, leading to a strategic tripling of capacity.
Amneal increased its capital expenditure expectations from $110 million to $150 million to support US injectable expansion and immediate market demand for Women's Health products.
Management noted that severe flooding occurred at a facility in Gujarat, India. All employees at the site are safe, and while the flooding represents a localized operational risk, management expects a limited impact on select products with operations resuming within weeks.
Estimated negative impact from the India facility flood on 2026 guidance.
The estimated $20 million negative impact from the India flooding is expected to be offset by higher profitability and lower interest expense resulting from debt repricing.
The company successfully repriced its $2.084 billion Term Loan B, reducing interest expense by 50 basis points and yielding $12 million in annual savings.
M&A strategy and pipeline developments
Amneal is shifting its M&A focus toward specialty assets, specifically targeting CNS and oncology to leverage existing commercial infrastructure.
The company framed the pending Kashiv acquisition as a pivot toward becoming a fully integrated global biosimilar player by controlling development through commercial supply.
The Kashiv transaction will provide $400 million to $500 million in financial benefits.
The Kashiv acquisition is also expected to provide a deleveraging path, with management targeting net leverage below 3x by 2028.
Regarding specific products, Lanreotide remains on track for a Q3 2026 launch. The XOLAIR biosimilar launch is expected very late in 2026 or may move into January 2027, with zero revenue currently modeled for 2026.
The adoption of CREXONT is shifting toward general neurologists, a group that writes 80% of Parkinson's prescriptions.
Iohexol is projected to become a $50-plus million opportunity starting in 2027 as capacity expands, though 2026 revenue is not expected to be meaningful.
Amneal's long-term strategy targets $1 billion to $2 billion in new revenue from the Affordable Medicines pipeline through 2030, supported by 12 to 15 high-value complex ANDA filings planned for the current year.
Management intends to use excess cash flow to add branded pipeline assets both internally and externally starting next year.
The company also holds exclusive commercial rights in specific markets, including India and Egypt, which are currently being evaluated for launch potential.
Amneal's management also viewed US drug shortages as a strategic opportunity to position its domestic manufacturing footprint as a solution for supply chain resiliency.
Partnership efforts are progressing with plans to have operational plants by 2029 and 2030 to support global supply.
Management is pursuing a 'full basket' strategy, expecting all strengths to be approved by year-end to capture a larger market share.
